新生儿与儿科急性肾损伤实验室评估:IFCC国际调查现状与启示
IFCC儿科实验室医学新兴技术委员会向北美和欧洲10个成员国发放12题调查,回收7国180份回复。仅20%报告AKI分期,52.7%使用推荐酶法肌酐但仅32%采用年龄相关参考区间;19家实验室引入新标志物,以胱抑素C(12家)和NGAL(5家)为主。调查显示新生儿与儿科AKI识别实践差异大,缺乏胎龄依赖肌酐参考区间是可靠诊断的关键障碍。
要点
- 仅20%实验室报告AKI分期,年龄相关肌酐参考区间使用率仅32%。
- 52.7%使用推荐酶法肌酐,新标志物以胱抑素C和NGAL为主但普及受限。
- 缺乏新生儿胎龄依赖肌酐参考区间是可靠AKI诊断的关键障碍。
核心结论
- 新生儿与儿科AKI实验室识别方法存在显著差异,AKI分期和年龄适宜肌酐参考区间使用有限。
- 新标志物仅少数实验室应用,广泛推广受检测可及性、成本和缺乏明确指南约束。
研究设计与样本
- IFCC儿科实验室医学新兴技术委员会发放12题调查,覆盖北美和欧洲10个成员国。
- 回收7个国家180份回复,评估实验室医学中AKI识别现状。
主要发现
- 仅20%回复报告AKI分期。
- 52.7%实验室使用推荐酶法肌酐,仅32%使用年龄相关参考区间。
- 19家实验室引入新标志物,胱抑素C 12家、NGAL 5家。
关键数值与推荐
- 推荐酶法肌酐使用率52.7%,年龄相关参考区间使用率32%。
- AKI分期报告率20%,新标志物引入实验室19家。
临床怎么用
- 实验室应关注酶法肌酐和年龄相关参考区间的规范使用以提高儿科AKI识别一致性。
- 引入胱抑素C或NGAL等新标志物需结合检测可及性、成本和指南证据综合评估。
局限性
- 调查仅覆盖北美和欧洲7个国家180份回复,代表性有限。
- 调查为自报实践,未与患者结局或实验室实际检测质量关联验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Identification of acute kidney injury (AKI) in neonatology and paediatrics continues to present challenges to laboratories. Emerging biomarkers are being developed which may offer early detection but haven't been adopted in current guidelines yet. The aim of this IFCC survey was to characterise current laboratory practices in paediatric settings and identify key drivers and barriers to implementing emerging biomarkers in routine practice. METHODS: A twelve-question survey was distributed by the International Federation of Clinical Chemistry and Laboratory Medicine's Committee of Emerging Technologies in Paediatric Laboratory Medicine to 10 member countries in North America and Europe to assess the current state of AKI identification in laboratory medicine. RESULTS: 180 responses were received from seven countries. Only 20 % reported AKI staging. 52.7 % of laboratories used the recommended enzymatic creatinine method with only 32 % using an age-related reference interval. 19 laboratories had introduced novel biomarkers into practice with Cystatin-C (12) and neutrophil gelatinase-associated lipocalin (NGAL) (5) being the most popular. CONCLUSIONS: This survey demonstrates substantial variation in laboratory approaches to AKI identification in neonatal and paediatric settings with limited use of AKI staging and inconsistent use of age-appropriate creatinine reference intervals. The lack of neonatal and gestational age-dependent creatinine reference intervals remains a key barrier to reliable neonatal AKI diagnosis. While a minority of laboratories have implemented emerging biomarkers (most commonly cystatin C and NGAL), wider adoption is constrained by assay availability, cost and absence of clear guidance. These findings highlight priority areas for harmonisation and guideline development to support evidence-based implementation of emerging biomarkers in routine practice.
引用
- Lang T, Omosule CL, Greaves R, et al. Assessing neonatal and paediatric acute kidney injury: current practices and insights from the IFCC C-ETPLM International Laboratory Survey. Clin Chem Lab Med. 2026. PMID: 42415250. doi:10.1515/cclm-2026-0626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。